The European Association for the Study of Diabetes

Diabetes Care

Volumn 28, Issue 5, 2005, Pages 1250-1257

  Bloomgarden, Zachary T ^a,b  

^a Mount Sinai School of Medicine ^*

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIAZOLIDINE DERIVATIVE; VALSARTAN;

CONFERENCE PAPER; CONGESTIVE HEART FAILURE; GLUCOSE HOMEOSTASIS; HEMODIALYSIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER; NONHUMAN; POPULATION RESEARCH;

DIABETES COMPLICATIONS; EUROPE; HEART FAILURE, CONGESTIVE; HOMEOSTASIS; HUMANS; THIAMINE;

EID: 18144406826     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.5.1250     Document Type: Conference Paper

References (53)

1. Van Biesen W, Vanholder RC, Veys N, Dhondt A, Lameire NH: An evaluation of an integrative care approach for end-stage renal disease patients. J Am Soc Nephrol 11:116-125, 2000
2. Fenton SS, Schaubel DE, Desmeules M, Morrison HI, Mao Y, Copleston P, Jeffery JR, Kjellstrand CM: Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am J Kidney Dis 30:334-342, 1997
3. Locatelli F, Marcelli D, Conte F, D'Amico M, Del Vecchio L, Limido A, Malberti F, Spotti D: Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. J Am Soc Nephrol 12:2411-2417, 2001
4. Konner K: Primary vascular access in diabetic patients: an audit. Nephrol Dial Transplant 15:1317-1325, 2000
5. Quellhorst E: Insulin therapy during peritoneal dialysis: pros and cons of various forms of administration. J Am Soc Nephrol 13:S92-S96, 2002
6. Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, Hulbert-Shearon T, Jones CA, Bloembergen WE: Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 11:556-564, 2000
7. Vanholder R, Heering P, Loo AV, Biesen WV, Lambert MC, Hesse U, Vennet MV, Grabensee B, Lameire N: Reduced incidence of acute renal graft failure in patients treated with peritoneal dialysis compared with hemodialysis. Am J Kidney Dis 33:934-940, 1999
8. Papalois BE, Troppmann C, Gruessner AC, Benedetti E, Sutherland DE, Gruessner RW: Long-term peritoneal dialysis before transplantation and intra-abdominal infection after simultaneous pancreas-kidney transplantations. Arch Surg 131:761-766, 1996
9. Koch M, Gradaus F, Schoebel FC, Leschke M, Grabensee B: Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. Nephrol Dial Transplant 12:1187-1191, 1997
10. Fernando DJ, Hutchison A, Veves A, Gokal R, Boulton AJ: Risk factors for non-ischaemic foot ulceration in diabetic nephropathy. Diabet Med 8:223-225, 1991
11. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27:394-401, 1996
12. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134:629-636, 2001
13. Manske CL, Wang Y, Rector T, Wilson RF, White CW: Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure. Lancet 340:998-1002, 1992
14. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yanovski JA, Veis JH: Immunologic function and survival in hemodialysis patients. Kidney Int 54:236-244, 1998
15. Stenvinkel P, Barany P, Heimburger O, Pecoits-Filho R, Lindholm B: Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int Suppl 80:103-108, 2002
16. Mendelssohn DC, Kua BT, Singer PA: Referral for dialysis in Ontario. Arch Intern Med 155:2473-2478, 1995
17. Schramm W, Bergrem H, Cromme P, Feest T, Borch-Johnsen K, Feldt-Rasmussen B, Landgraf R: First referral of diabetic patients to a nephrologist. Diabet Med 20:689-690, 2003
18. Huisman RM: The deadly risk of late referral. Nephrol Dial Transplant 19:2175-2180, 2004
19. Piccoli GB, Grassi G, Mezza E, Gai M, Iacuzzo C, Bechis F, Biancone L, Jeantet A, Dani F, Perin PC, Segoloni GP: Early referral of type 2 diabetic patients: are we ready for the assault? Nephrol Dial Transplant 17:1241-1247, 2002
20. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB: The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27:1879-1884, 2004
21. Amato L, Paolisso G, Cacciatore F, Ferrara N, Ferrara P, Canonico S, Varricchio M, Rengo F: Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly: the Osservatorio Geriatrico Regione Campania Group. Diabetes Metab 23:213-218, 1997
22. Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG: Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 24:5-10, 2001
23. Pfister R, Scholz M, Wielckens K, Erdmann E, Schneider CA: Use of NT-proBNP in routine testing and comparison to BNP. Eur J Heart Fail 6:289-293, 2004
24. Magnusson M, Melander O, Israelsson B, Grubb A, Groop L, Jovinge S: Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 27:1929-1935, 2004
25. Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB, Nesto RW, Wilson PW, Vasan RS: Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 107:448-454, 2003
26. Goraya TY, Leibson CL, Palumbo PJ, Weston SA, Killian JM, Pfeifer EA, Jacobsen SJ, Frye RL, Roger VL: Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol 40:946-953, 2002
27. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull WJr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW: A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 92:1355-1374, 1995
28. Liang CP, Han S, Okamoto H, Carnemolla R, Tabas I, Accili D, Tall AR: Increased CD36 protein as a response to defective insulin signaling in macrophages. J Clin Invest 113:764-773, 2004
29. Watts GF, Playford DA, Croft KD, Ward NC, Mori TA, Burke V: Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in type II diabetes mellitus. Diabetologia 45:420-426, 2002
30. Creager MA, Luscher TF, Cosentino F, Beckman JA: Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 108:1527-1532, 2003
31. Luscher TF, Creager MA, Beckman JA, Cosentino F: Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Circulation 108:1655-1661, 2003
32. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension: systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 276:1886-1892, 1996
33. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schoik A, Smith B, Zanchetti A, VALUE Trial Group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363:2022-2031, 2004
34. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
35. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 316:823-828, 1998
36. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
37. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRC-HOPE substudy. Lancet 355:253-259, 2000
38. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhiquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, the LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): at randomised trial against atenolol. Lancet 359:1004-1010, 2002
39. Haas SJ, Vos T, Gilbert RE, Krum H: Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 146:848-853, 2003
40. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, Rhodes S, Barrett M, Fonarow GC, Greenberg E, Heidenreich PA, Knabel T, Konstam MA, Steimle A, Warner Stevenson L: Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41:1529-1538, 2003
41. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, the CHARM Investigators and Committees: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362:759-766, 2003
42. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A, the Carvedilol Or Metoprolol European Trial Investigators: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362:7-13, 2003
43. Cosin J, Diez J: Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 4:507-513, 2002
44. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981-2997, 2002
45. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R, the American Heart Association, the American Diabetes Association: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108:2941-2948, 2003
46. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001
47. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M: Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9:294-299, 2003
48. Hammes HP, Lin J, Renner O, Shani M, Lundqvist A, Betsholtz C, Brownlee M, Deutsch U: Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 51:3107-3112, 2002
49. Hanahan D: Signaling vascular morphogenesis and maintenance. Science 277:48-50, 1997
50. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ: Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52:2110-2120, 2003
51. Thornalley PJ, Jahan I, Ng R: Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human red blood cells during hyperglycaemia by thiamine in vitro. J Biochem 129:543-549, 2001
52. Babaei-Jadidi R, Karachalias N, Kupich C, Ahmed N, Thornalley PJ: High-dose thiamine therapy counters dyslipidaemia in streptozotocin-induced diabetic rats. Diabetologia 47:2235-2246, 2004
53. Obici S, Zhang BB, Karkanias G, Rossetti L: Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 8:1376-1382, 2002